Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of D-cycloserine on negative symptoms in schizophrenia.
Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP. Duncan EJ, et al. Schizophr Res. 2004 Dec 1;71(2-3):239-48. doi: 10.1016/j.schres.2004.03.013. Schizophr Res. 2004. PMID: 15474895 Review.
Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.
Edgar CJ, Blaettler T, Bugarski-Kirola D, Le Scouiller S, Garibaldi GM, Marder SR. Edgar CJ, et al. Psychiatry Res. 2014 Aug 15;218(1-2):219-24. doi: 10.1016/j.psychres.2014.04.009. Epub 2014 Apr 13. Psychiatry Res. 2014. PMID: 24809242 Clinical Trial.
Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms.
Schooler NR, Buchanan RW, Laughren T, Leucht S, Nasrallah HA, Potkin SG, Abi-Saab D, Berardo CG, Bugarski-Kirola D, Blaettler T, Edgar CJ, Nordstroem AL, O'Gorman C, Garibaldi G. Schooler NR, et al. Schizophr Res. 2015 Mar;162(1-3):169-74. doi: 10.1016/j.schres.2014.12.001. Epub 2015 Jan 9. Schizophr Res. 2015. PMID: 25579053 Review.
Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.
Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, Davidson M, Lombardo I, Bowie CR, Buchanan RW, Bugarski-Kirola D, Carpenter WT, Csernansky JT, Dago PL, Durand DM, Frese FJ, Goff DC, Gold JM, Hooker CI, Kopelowicz A, Loebel A, McGurk SR, Opler LA, Pinkham AE, Stern RG. Keefe RS, et al. Among authors: bugarski kirola d. Schizophr Bull. 2016 Jan;42(1):19-33. doi: 10.1093/schbul/sbv111. Epub 2015 Sep 11. Schizophr Bull. 2016. PMID: 26362273 Free PMC article.
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
Bugarski-Kirola D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, Marques TR, Garibaldi G, Kapur S. Bugarski-Kirola D, et al. Lancet Psychiatry. 2016 Dec;3(12):1115-1128. doi: 10.1016/S2215-0366(16)30344-3. Epub 2016 Nov 2. Lancet Psychiatry. 2016. PMID: 27816567 Clinical Trial.
19 results